3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Fallopian Tube Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-sensitive Prostate Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
12
Carboplatin
12
Bevacizumab
11
liposomal doxorubicin
8
Specimen Handling
8
olaparib
7
Magnetic Resonance Spectroscopy
7
Topotecan
4
Gemcitabine
4
Biopsy
4
pembrolizumab
3
mirvetuximab soravtansine
3
Taxes
3
Doxorubicin
3
sarilumab
2
niraparib
2
cemiplimab
2
cediranib
2
Immunoglobulin G
2
Disulfides
2
1-dodecylpyridoxal
2
trastuzumab deruxtecan
1
tocilizumab
1
sotorasib
1
peposertib
1
pelcitoclax
1
palbociclib
1
nilotinib
1
neratinib
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
niraparib
×
30 days
×
Clear all
NCT04295577
2026-05-13
MONITOR-UK
Royal Marsden NHS Foundation Trust
Completed
388 enrolled
NCT06915025
2026-05-04
OVATION-3
Imunon
Phase 3
Recruiting
500 enrolled